Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Akari Therapeutics (AKTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,442
  • Shares Outstanding, K 11,780
  • Annual Sales, $ 0 K
  • Annual Income, $ -32,570 K
  • 36-Month Beta -7.65
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.21

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.77 +12.43%
on 05/23/18
2.16 -7.87%
on 06/15/18
+0.08 (+4.19%)
since 05/22/18
3-Month
1.70 +17.06%
on 03/28/18
2.32 -14.22%
on 05/07/18
-0.01 (-0.50%)
since 03/22/18
52-Week
1.70 +17.06%
on 03/28/18
11.95 -83.35%
on 09/21/17
-2.78 (-58.28%)
since 06/22/17

Most Recent Stories

More News
Akari Therapeutics to Present Poster at the 23rd Congress of the European Hematology Association

Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today...

AKTX : 1.99 (-0.50%)
Market Trends Toward New Normal in Independent Bank, First Busey, American Public Education, The First Bancshares, Northfield, and Akari Therapeutics -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Independent Bank Corporation...

AKTX : 1.99 (-0.50%)
FBMS : 35.90 (+1.27%)
IBCP : 26.30 (+0.96%)
NFBK : 17.20 (+0.82%)
BUSE : 32.98 (+0.30%)
APEI : 43.65 (+0.58%)
Akari Therapeutics Receives Notice Related to Delay in 20-F Filing

Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today...

AKTX : 1.99 (-0.50%)
Blog Exposure - Tetraphase Pharma Announced Data Presentations from IGNITE4 Study at 28th European Congress of Clinical Microbiology and Infectious Diseases

Stock Monitor: Akari Therapeutics Post Earnings Reporting

AKTX : 1.99 (-0.50%)
TTPH : 4.01 (+0.50%)
Analysis: Positioning to Benefit within ForeScout Technologies, CommerceHub, Newtek Business Services, Credit Acceptance, Akari Therapeutics, and Brady -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ForeScout Technologies, Inc....

NEWT : 19.15 (-0.26%)
AKTX : 1.99 (-0.50%)
CACC : 363.55 (-1.42%)
BRC : 39.80 (-0.13%)
CHIAV : 13.53 (+12.75%)
CHUBA : 22.73 (+0.04%)
FSCT : 34.05 (-3.49%)
Akari Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Clinical Progress

-- Received Regulatory Clearance in Europe to Open First Clinical Trial Site for Phase III PNH Naive Trial

AKTX : 1.99 (-0.50%)
Akari Therapeutics To Report Fourth Quarter and Full Year 2017 Financial and Operational Results and Host Conference Call on March 21, 2018

Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today...

AKTX : 1.99 (-0.50%)
Akari Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Akari Therapeutics, Plc (NASDAQ:AKTX) ("Akari" or "the Company"), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and...

AKTX : 1.99 (-0.50%)
Market Trends Toward New Normal in NV5 Global, Akari Therapeutics, American Public Education, Twilio, Monroe Capital, and Jabil -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of NV5 Global, Inc. (NASDAQ:NVEE),...

AKTX : 1.99 (-0.50%)
TWLO : 55.25 (-3.00%)
MRCC : 13.62 (unch)
JBL : 28.30 (+4.31%)
NVEE : 69.35 (+1.76%)
APEI : 43.65 (+0.58%)
Kadmon Holdings (KDMN) Jumps: Stock Rises 9.3%

Kadmon Holdings, Inc. (KDMN) was a big mover last session, as the company saw its shares more than 9% on the day amid huge volumes.

AKTX : 1.99 (-0.50%)
KDMN : 3.87 (+4.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade AKTX with:

Business Summary

Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company's lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5,...

See More

Key Turning Points

2nd Resistance Point 2.11
1st Resistance Point 2.05
Last Price 1.99
1st Support Level 1.95
2nd Support Level 1.91

See More

52-Week High 11.95
Fibonacci 61.8% 8.03
Fibonacci 50% 6.82
Fibonacci 38.2% 5.62
Last Price 1.99
52-Week Low 1.70

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar